# Ocugen licenses investigational OCU400 gene therapy for Middle East and North Africa

_Published Wednesday, October 14, 2026 at 8:18 AM EDT · Science · Latest · Tier 2 — Notable_

![Ocugen licenses investigational OCU400 gene therapy for Middle East and North Africa — Primary](https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png)

Ocugen announced an exclusive licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for OCU400 in the Middle East and North Africa. OCU400 is an investigational gene therapy for retinitis pigmentosa, a disease that causes vision loss.

The agreement provides an upfront license fee, initial development milestone payments of up to $4 million, potential sales milestone payments of up to $255 million and royalties of 22% of net sales. Ocugen will manufacture and supply the therapy for commercial use. OCU400 remains in the Phase 3 liMeliGhT trial, with topline data expected in the first quarter of 2027 before planned U.S. and European regulatory submissions.

## Sources

- [RTTNews](https://www.rttnews.com/3698917/ocugen-licenses-ocu400-gene-therapy-to-roots-pharmaceutical-for-mena-region.aspx)

---
Canonical: https://techandbusiness.org/newswire/jJs-NwMzDVukXZlvND4PlD
Published: 2026-10-14T12:18:43.430Z
Story chronology: 2026-10-14T11:49:14.000Z
Retrieved: 2026-10-14T14:52:19.012Z
Publisher: Tech & Business (techandbusiness.org)